{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1363670318326908416.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1002/hep.21723"}},{"identifier":{"@type":"URI","@value":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fhep.21723"}},{"identifier":{"@type":"URI","@value":"https://journals.lww.com/01515467-200708000-00015"}}],"dc:title":[{"@value":"Peginterferon alpha‐2b is safe and effective in HBeAg‐positive chronic hepatitis B patients with advanced fibrosis† ‡ §"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1383670318326908417","@type":"Researcher","foaf:name":[{"@value":"Erik H. C. J. Buster"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318326908424","@type":"Researcher","foaf:name":[{"@value":"Bettina E. Hansen"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318326908416","@type":"Researcher","foaf:name":[{"@value":"Maria Buti"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318326908421","@type":"Researcher","foaf:name":[{"@value":"Jean Delwaide"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318326908423","@type":"Researcher","foaf:name":[{"@value":"Claus Niederau"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318326908425","@type":"Researcher","foaf:name":[{"@value":"Peter P. Michielsen"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318326908420","@type":"Researcher","foaf:name":[{"@value":"Robert Flisiak"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318326908422","@type":"Researcher","foaf:name":[{"@value":"Pieter E. Zondervan"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318326908419","@type":"Researcher","foaf:name":[{"@value":"Solko W. Schalm"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318326908418","@type":"Researcher","foaf:name":[{"@value":"Harry L. A. Janssen"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"02709139"}],"prism:publicationName":[{"@value":"Hepatology"}],"dc:publisher":[{"@value":"Ovid Technologies (Wolters Kluwer Health)"}],"prism:publicationDate":"2007-08","prism:volume":"46","prism:number":"2","prism:startingPage":"388","prism:endingPage":"394"},"reviewed":"false","dc:rights":["http://doi.wiley.com/10.1002/tdm_license_1.1"],"url":[{"@id":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fhep.21723"},{"@id":"https://journals.lww.com/01515467-200708000-00015"}],"createdAt":"2007-06-29","modifiedAt":"2024-12-01","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360565168116348928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"JSH Guidelines for the Management of Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360857593811432832","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Are Humanized Mouse Models Useful for Basic Research of Hepatocarcinogenesis through Chronic Hepatitis B Virus Infection?"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771619840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Two cases of acute hepatitis due to hepatitis E virus that are indigenous to Kitakyushu: a case report"},{"@language":"ja","@value":"北九州に土着したE型肝炎ウイルス株による急性肝炎の2例"},{"@value":"B型肝炎治療ガイドライン(第1.1版)"},{"@language":"ja-Kana","@value":"Bガタ カンエン チリョウ ガイドライン(ダイ1.1ハン)"},{"@language":"ja-Kana","@value":"キタキュウシュウ ニ ドチャク シタ Eガタ カンエンウイルスカブ ニ ヨル キュウセイ カンエン ノ 2レイ"},{"@value":"Guidelines for the management of hepatitis B virus infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282681421863424","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"The Forefront of Treatment of Type B/C Chlonic Hepatitis."},{"@language":"ja","@value":"B型・C型慢性肝炎治療の最前線"},{"@value":"医学と医療の最前線 B型・C型慢性肝炎治療の最前線"},{"@language":"ja-Kana","@value":"イガク ト イリョウ ノ サイゼンセン Bガタ Cガタ マンセイ カンエン チリョウ ノ サイゼンセン"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1002/hep.21723"},{"@type":"CROSSREF","@value":"10.1111/hepr.12269_references_DOI_KrlfLjzqzHTLaMqYwExOtUtZCza"},{"@type":"CROSSREF","@value":"10.2169/naika.99.3080_references_DOI_KrlfLjzqzHTLaMqYwExOtUtZCza"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.402_references_DOI_KrlfLjzqzHTLaMqYwExOtUtZCza"},{"@type":"CROSSREF","@value":"10.3390/v13101920_references_DOI_KrlfLjzqzHTLaMqYwExOtUtZCza"}]}